Drugs / Beinaglutide
Beinaglutide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05005741 | May 2021 → Dec 2023 | obesity disorder, type 2 diabetes mellitus | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03987308 | Jul 2019 → Sep 2025 overdue | diabetes mellitus, noninsulin-dependent, 2 | Beijing Hospital | Recruiting | No outcome recorded |
| — | NCT03829891 | Aug 2018 → Dec 2019 | type 2 diabetes mellitus | Xijing Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02333591 Comparator | Jul 2016 → Jun 2018 | coronary microvascular disorder | Mette Zander | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beinaglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03987308 ↗ |
| Known as | Glp-1 (7-36) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095267 ↗ |
| Known as | Glucagon like peptide-i (7-36) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095267 ↗ |
| Known as | GlucagonLikePeptide-1 (7-36) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02333591 ↗ |
| Action | Activate | “novel glucagon-like peptide-1 receptor agonists beinaglutide.” PMID 37864379 ↗ Oct 2023 |
| Modality | Protein / enzyme biologic | — CHEMBL5095267 ↗ |
| Route | Intravenous | “Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.” NCT02333591 ↗ |